Nimodipine and inhibition of alpha adrenergic activation of the isolated canine saphenous vein. 1985

J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte

The vascular smooth muscle of the canine saphenous vein contains both postjunctional alpha-1 and alpha-2 adrenoceptors. Experiments were designed to elucidate the relationship between alpha adrenoceptor subtypes and sensitivity to calcium entry blockade. Rings of canine saphenous vein were mounted at optimal length for isometric tension recording in organ chambers filled with physiological salt solution. Nimodipine inhibited potassium-induced contractions and depressed contractions to norepinephrine in the presence of prazosin, an alpha-1 adrenoceptor antagonist, but not under control conditions or in the presence of the alpha-2 adrenoceptor antagonist, rauwolscine. Nimodipine depressed the maximal response to B-HT 920, an alpha-2 adrenergic agonist and St-587, a partial alpha-1 adrenergic agonist, but did not affect that to cirazoline, a full alpha-1 adrenergic agonist. However, after treatment with phenoxybenzamine, nimodipine depressed the response to cirazoline. Nimodipine inhibited contractions to tyramine under control conditions or after prazosin but not after rauwolscine. Incubation in calcium-free solution depressed responses to St-587 and B-HT 920 more than those to cirazoline. Incubation in calcium-free solution plus ethylene glycol bis(beta-aminoethyl ether)-N,N-tetraacetic acid abolished responses to all alpha adrenergic agonists. These results suggest that the sensitivity to calcium entry blockade of alpha adrenergic responses is not determined by the subtype of alpha adrenoceptor. Rather, our findings support the concept that it is the efficacy of the agonist-receptor interaction or the efficiency of receptor-response coupling that determines the effect of calcium entry blockade on the adrenergic response.

UI MeSH Term Description Entries
D008297 Male Males
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D009553 Nimodipine A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. Admon,Bay e 9736,Brainal,Calnit,Kenesil,Modus,Nimodipin Hexal,Nimodipin-ISIS,Nimodipino Bayvit,Nimotop,Nymalize,Remontal,Bayvit, Nimodipino,Hexal, Nimodipin,Nimodipin ISIS,e 9736, Bay
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females

Related Publications

J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
January 1987, General pharmacology,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
December 1978, The Journal of pharmacology and experimental therapeutics,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
March 1992, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
March 1992, The Journal of pharmacology and experimental therapeutics,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
March 1982, Archives internationales de pharmacodynamie et de therapie,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
November 1998, Acta anaesthesiologica Scandinavica,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
April 1989, The Journal of pharmacology and experimental therapeutics,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
August 1986, The Journal of pharmacology and experimental therapeutics,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
January 1987, Pharmacology,
J P Cooke, and T J Rimele, and N A Flavahan, and P M Vanhoutte
January 1991, Journal of neural transmission. Supplementum,
Copied contents to your clipboard!